--- title: "STARCOIN and Huamei Haibo signed a memorandum of understanding to explore cooperation in the integration of biotechnology and the digital economy" type: "News" locale: "en" url: "https://longbridge.com/en/news/281146650.md" description: "STARCOIN GROUP signed a memorandum of understanding with Huamei Haibo to explore cooperation in biotechnology and the digital economy. Both parties will leverage resource sharing and complementary advantages to identify potential collaboration opportunities, including equity investment, asset restructuring, and Web3.0 health chains. Huamei Haibo focuses on the research and development of AI-driven cell manufacturing equipment, while STARCOIN GROUP will utilize its technological advantages to accelerate the integration of Web3.0 and cell technology, enhance competitiveness, and promote the intelligent development of the health industry" datetime: "2026-03-31T07:47:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281146650.md) - [en](https://longbridge.com/en/news/281146650.md) - [zh-HK](https://longbridge.com/zh-HK/news/281146650.md) --- # STARCOIN and Huamei Haibo signed a memorandum of understanding to explore cooperation in the integration of biotechnology and the digital economy STARCOIN GROUP (00399.HK) and its strong subsidiary announced the signing of a memorandum of understanding for strategic cooperation with Huamei Haibo, where both parties will collaborate to explore new possibilities for the integration of biotechnology and the digital economy. According to the memorandum of understanding, the contracting parties will comprehensively explore potential cooperation opportunities in multiple fields based on the principles of complementary advantages, resource sharing, and joint development. This includes potential equity investments, asset restructuring, Web3.0 health chains, business cooperation, joint market development, joint financing, and other capital operation arrangements. At the same time, both parties will also explore the possibility of incorporating Huamei Haibo or its related businesses and/or assets into the merger and acquisition transactions of the U.S. special purpose acquisition company in which the group and/or its assets or businesses participate, further achieving resource integration and maximizing value. It is reported that Huamei Haibo is a biotechnology supplier based in Chongqing, focusing on the research and development of cell manufacturing equipment driven by artificial intelligence technology and the upgrading of medical services, with technical accumulation and industrial resources in the field of cell technology. Looking ahead, STARCOIN GROUP will leverage Huamei Haibo's core advantages in cell technology, equipment manufacturing, and industrial resources to accelerate the deep integration of Web3.0 health chains and cell technology, enhance core competitiveness, and assist the health industry in moving towards intelligence and inclusiveness ### Related Stocks - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [00399.HK](https://longbridge.com/en/quote/00399.HK.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [513290.CN](https://longbridge.com/en/quote/513290.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) ## Related News & Research - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)